Folotyn for Non-Hodgkin's Lymphoma Jacksonville FL

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Morris Seligman Dees III, MD
5742 Booth Rd
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Ok Coll Of Med, Oklahoma City Ok 73190
Graduation Year: 1993

Data Provided by:
Paul Allen Pitel, MD
(904) 390-3561
807 Childrens Way
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Brown Univ Program In Med, Providence Ri 02912
Graduation Year: 1976
Hospital
Hospital: Baptist Med Ctr, Jacksonville, Fl
Group Practice: Nemours Children's Clinic

Data Provided by:
Leann Lessl Fox, MD
(904) 390-3674
807 Childrens Way
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of South Al Coll Of Med, Mobile Al 36688
Graduation Year: 1988

Data Provided by:
Robert Allen Joyce
(904) 493-5100
1235 San Marco Blvd
Jacksonville, FL
Specialty
Hematology / Oncology

Data Provided by:
Eric Stuart Sandler, MD
(904) 390-3793
807 Childrens Way
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Vt Coll Of Med, Burlington Vt 05405
Graduation Year: 1985
Hospital
Hospital: Baptist Med Ctr, Jacksonville, Fl; Shands Jacksonville Med Ctr, Jacksonville, Fl
Group Practice: Nemours Childrens Clinic

Data Provided by:
Jeffrey Harris
(904) 493-5100
1235 San Marco Blvd
Jacksonville, FL
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
Dr.Yousif Abubakr
(904) 739-7779
5742 Booth Road
Jacksonville, FL
Gender
M
Education
Medical School: Univ Of Khartoum, Fac Of Med, Khartoum
Year of Graduation: 1986
Speciality
Oncologist
General Information
Hospital: Baptist Med Ctr, Jacksonville, Fl
Accepting New Patients: Yes
RateMD Rating
4.9, out of 5 based on 4, reviews.

Data Provided by:
Manisha Makker Bansal
(904) 390-3600
807 Childrens Way
Jacksonville, FL
Specialty
Pediatric Hematology-Oncology

Data Provided by:
Yousif A Abubakr, MD
(904) 739-7779
5742 Booth Rd
Jacksonville, FL
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Khartoum, Fac Of Med, Khartoum, Sudan
Graduation Year: 1986
Hospital
Hospital: Baptist Med Ctr, Jacksonville, Fl; Memorial Hosp, Jacksonville, Fl
Group Practice: Hematology-Oncology

Data Provided by:
Rizwan D Nurani
(904) 636-6911
5742 Booth Rd
Jacksonville, FL
Specialty
Radiation Oncology

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Mailing Address:
Jacksonville Magazine
1261 King St.
Jacksonville, FL 32204
TEL: (904) 389-3622
FAX: (904) 389-3628
E-mail: mail@jacksonvillemag.com